DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Questions
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s12032-012-0168-1, but it redirected us to https://link.springer.com/article/10.1007/s12032-012-0168-1. The analysis below is for the second page.

Title[redir]:
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients | Medical Oncology
Description:
Dendritic cells may be successfully used to induce in vivo-specific anti-tumor responses when combined with the appropriate antigen in the appropriate context. The purpose of this study was to evaluate efficacy of peptide-loaded DC vaccine in high-risk stage III melanoma patients after lymph node dissection (LND). HLA-A2+, -A1+, or -A3+ melanoma patients (N = 22), stage III, N1b-N3, received 5–16 (median: 11) DC vaccines loaded with MHC class-I-restricted melanoma peptides respective to the patient’s haplotype, and with autologous tumor lysate, if available. Vaccinated patients were matched to unvaccinated stage III controls (22 of 869) by sex, number of metastatic lymph nodes, extracapsular involvement, LND type, Breslow stage, and ulceration. Vaccination elicited cutaneous delayed-type hypersensitivity (DTH) or/and IFN-γ-producing CD8+ cell response to melanoma peptides in 15 of 22 patients. Three-year overall survival (OS) rate was 68.2% in the vaccinated group versus 25.7% in the control group, P value accounting for matching: 0.0290. In a Cox regression model, hazard ratio (HR) for death of vaccinated patients was 0.31 [95% confidence interval (CI): 0.10–0.94]. The corresponding values for 3-year disease-free survival rate were 40.9 versus 14.5%, P = 0.1083; HR of recurrence for vaccinated, 0.46 (95% CI: 0.18–1.22). There was no grade >1 toxicity. The DC/peptide vaccine was well tolerated and elicited immune responses to melanoma antigens. Vaccinated patients had significantly longer OS after LND than the matched controls, but a significant improvement in the primary endpoint DFS was not achieved.

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We find it hard to spot revenue streams.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Doi.org has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

google, scholar, article, pubmed, melanoma, cas, dendritic, patients, cells, cancer, cell, vaccination, vaccine, immunol, factor, stage, tumor, clinical, res, oncol, adjuvant, iii, markowicz, vaccines, immunotherapy, med, human, responses, antigen, blood, clin, granulocytemacrophage, colonystimulating, oncology, rutkowski, autologous, metastatic, survival, immune, access, phase, trial, privacy, cookies, content, vaccinated, peptide, generation, ann, progenitors,

Topics {✒️}

granulocyte/macrophage colony-stimulating factor granulocyte-macrophage colony-stimulating factor peptide-pulsed dendritic cells vivo-specific anti-tumor responses peptide-loaded dc vaccine month download article/chapter melana/mart-127-35-specific ctls dendritic cell-based vaccination pubmed google scholar dc/peptide vaccine antigen-specific cd8+ ctls castration-resistant prostate cancer piotr rutkowski cd4+ t-cell responses prolonged relapse-free interval soft tissue/bone sarcoma author information authors dendritic cell immunotherapy dendritic cell vaccines peripheral-blood cell recovery human dendritic cells autologous tumor lysate multicenter randomized trial anna jakubowska-mucka dc vaccines loaded cell melanoma vaccine peptide vaccination dendritic cells loaded related subjects author correspondence dendritic langerhans cells functional dendritic cells immunostimulatory dendritic cells dendritic cell progenitors full article pdf tumor necrosis factor node-negative melanoma peripheral blood lymphocytes adjuvant immunotherapy dendritic cell growth multipeptide melanoma vaccine allogeneic tumor vaccine antigen-specific cd4+ vaccine adjuvant adjuvant vaccination privacy choices/manage cookies therapeutic vaccine development elicited immune responses anticancer therapy stage iv melanoma

Questions {❓}

Dendritic cell vaccines in melanoma: from promise to proof?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients
         description:Dendritic cells may be successfully used to induce in vivo-specific anti-tumor responses when combined with the appropriate antigen in the appropriate context. The purpose of this study was to evaluate efficacy of peptide-loaded DC vaccine in high-risk stage III melanoma patients after lymph node dissection (LND). HLA-A2+, -A1+, or -A3+ melanoma patients (N = 22), stage III, N1b-N3, received 5–16 (median: 11) DC vaccines loaded with MHC class-I-restricted melanoma peptides respective to the patient’s haplotype, and with autologous tumor lysate, if available. Vaccinated patients were matched to unvaccinated stage III controls (22 of 869) by sex, number of metastatic lymph nodes, extracapsular involvement, LND type, Breslow stage, and ulceration. Vaccination elicited cutaneous delayed-type hypersensitivity (DTH) or/and IFN-γ-producing CD8+ cell response to melanoma peptides in 15 of 22 patients. Three-year overall survival (OS) rate was 68.2% in the vaccinated group versus 25.7% in the control group, P value accounting for matching: 0.0290. In a Cox regression model, hazard ratio (HR) for death of vaccinated patients was 0.31 [95% confidence interval (CI): 0.10–0.94]. The corresponding values for 3-year disease-free survival rate were 40.9 versus 14.5%, P = 0.1083; HR of recurrence for vaccinated, 0.46 (95% CI: 0.18–1.22). There was no grade >1 toxicity. The DC/peptide vaccine was well tolerated and elicited immune responses to melanoma antigens. Vaccinated patients had significantly longer OS after LND than the matched controls, but a significant improvement in the primary endpoint DFS was not achieved.
         datePublished:2012-02-03T00:00:00Z
         dateModified:2012-02-03T00:00:00Z
         pageStart:2966
         pageEnd:2977
         sameAs:https://doi.org/10.1007/s12032-012-0168-1
         keywords:
            Adjuvant vaccination
            Cancer vaccine
            Dendritic cells
            Melanoma
            Melanoma peptide
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig5_HTML.gif
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:29
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sergiusz Markowicz
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Zbigniew I. Nowecki
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Piotr Rutkowski
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrzej W. Lipkowski
               affiliation:
                     name:Polish Academy of Sciences
                     address:
                        name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marzena Biernacka
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anna Jakubowska-Mucka
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tomasz Switaj
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aleksandra Misicka
               affiliation:
                     name:Polish Academy of Sciences
                     address:
                        name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Henryk Skurzak
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hanna Polowniak-Pracka
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Microbiology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jan Walewski
               affiliation:
                     name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                     address:
                        name:Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients
      description:Dendritic cells may be successfully used to induce in vivo-specific anti-tumor responses when combined with the appropriate antigen in the appropriate context. The purpose of this study was to evaluate efficacy of peptide-loaded DC vaccine in high-risk stage III melanoma patients after lymph node dissection (LND). HLA-A2+, -A1+, or -A3+ melanoma patients (N = 22), stage III, N1b-N3, received 5–16 (median: 11) DC vaccines loaded with MHC class-I-restricted melanoma peptides respective to the patient’s haplotype, and with autologous tumor lysate, if available. Vaccinated patients were matched to unvaccinated stage III controls (22 of 869) by sex, number of metastatic lymph nodes, extracapsular involvement, LND type, Breslow stage, and ulceration. Vaccination elicited cutaneous delayed-type hypersensitivity (DTH) or/and IFN-γ-producing CD8+ cell response to melanoma peptides in 15 of 22 patients. Three-year overall survival (OS) rate was 68.2% in the vaccinated group versus 25.7% in the control group, P value accounting for matching: 0.0290. In a Cox regression model, hazard ratio (HR) for death of vaccinated patients was 0.31 [95% confidence interval (CI): 0.10–0.94]. The corresponding values for 3-year disease-free survival rate were 40.9 versus 14.5%, P = 0.1083; HR of recurrence for vaccinated, 0.46 (95% CI: 0.18–1.22). There was no grade >1 toxicity. The DC/peptide vaccine was well tolerated and elicited immune responses to melanoma antigens. Vaccinated patients had significantly longer OS after LND than the matched controls, but a significant improvement in the primary endpoint DFS was not achieved.
      datePublished:2012-02-03T00:00:00Z
      dateModified:2012-02-03T00:00:00Z
      pageStart:2966
      pageEnd:2977
      sameAs:https://doi.org/10.1007/s12032-012-0168-1
      keywords:
         Adjuvant vaccination
         Cancer vaccine
         Dendritic cells
         Melanoma
         Melanoma peptide
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-012-0168-1/MediaObjects/12032_2012_168_Fig5_HTML.gif
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:29
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sergiusz Markowicz
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Zbigniew I. Nowecki
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Piotr Rutkowski
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrzej W. Lipkowski
            affiliation:
                  name:Polish Academy of Sciences
                  address:
                     name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marzena Biernacka
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anna Jakubowska-Mucka
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tomasz Switaj
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aleksandra Misicka
            affiliation:
                  name:Polish Academy of Sciences
                  address:
                     name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Henryk Skurzak
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hanna Polowniak-Pracka
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Microbiology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jan Walewski
            affiliation:
                  name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
                  address:
                     name:Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:29
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Polish Academy of Sciences
      address:
         name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Polish Academy of Sciences
      address:
         name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Microbiology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
      name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
      address:
         name:Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sergiusz Markowicz
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Zbigniew I. Nowecki
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Piotr Rutkowski
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Andrzej W. Lipkowski
      affiliation:
            name:Polish Academy of Sciences
            address:
               name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Marzena Biernacka
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Anna Jakubowska-Mucka
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Tomasz Switaj
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Aleksandra Misicka
      affiliation:
            name:Polish Academy of Sciences
            address:
               name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Henryk Skurzak
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Hanna Polowniak-Pracka
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Microbiology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
      name:Jan Walewski
      affiliation:
            name:Maria Sklodowska-Curie Memorial Institute and Oncology Centre
            address:
               name:Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
      name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Neuropeptide Department, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warszawa, Poland
      name:Department of Immunology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Department of Microbiology, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
      name:Department of Lymphoid Malignancies, Maria Sklodowska-Curie Memorial Institute and Oncology Centre, Warszawa, Poland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(241)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Crossref

4.64s.